| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leiomyosarcoma | 8 | 2021 | 422 | 2.030 |
Why?
|
| Ovarian Neoplasms | 69 | 2021 | 4849 | 1.750 |
Why?
|
| Uterine Neoplasms | 13 | 2021 | 1420 | 1.720 |
Why?
|
| Gynecologic Surgical Procedures | 6 | 2018 | 284 | 1.630 |
Why?
|
| Fallopian Tube Neoplasms | 14 | 2019 | 328 | 1.110 |
Why?
|
| Hysterectomy | 12 | 2021 | 856 | 0.930 |
Why?
|
| Endometrial Neoplasms | 14 | 2023 | 1365 | 0.910 |
Why?
|
| Peritoneal Neoplasms | 18 | 2019 | 710 | 0.870 |
Why?
|
| Cystadenocarcinoma, Serous | 8 | 2020 | 473 | 0.640 |
Why?
|
| Vulvar Neoplasms | 4 | 2018 | 263 | 0.620 |
Why?
|
| Neoplasm Seeding | 2 | 2013 | 84 | 0.540 |
Why?
|
| Carcinoma, Endometrioid | 7 | 2021 | 276 | 0.530 |
Why?
|
| Genes, BRCA1 | 14 | 2013 | 753 | 0.520 |
Why?
|
| Ovariectomy | 10 | 2013 | 613 | 0.510 |
Why?
|
| Endometrium | 2 | 2016 | 403 | 0.460 |
Why?
|
| Carcinoma in Situ | 8 | 2021 | 791 | 0.440 |
Why?
|
| BRCA1 Protein | 8 | 2023 | 1149 | 0.430 |
Why?
|
| BRCA2 Protein | 5 | 2023 | 797 | 0.420 |
Why?
|
| Cystadenocarcinoma, Papillary | 8 | 2000 | 56 | 0.410 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 3 | 2019 | 194 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2015 | 4020 | 0.370 |
Why?
|
| Fallopian Tubes | 5 | 2018 | 178 | 0.330 |
Why?
|
| Precancerous Conditions | 8 | 2021 | 980 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2018 | 9277 | 0.300 |
Why?
|
| Genes, p53 | 11 | 2009 | 712 | 0.300 |
Why?
|
| Laparoscopy | 5 | 2015 | 2030 | 0.290 |
Why?
|
| Tumor Suppressor Protein p53 | 12 | 2018 | 2917 | 0.280 |
Why?
|
| Esophageal Neoplasms | 7 | 2011 | 1653 | 0.270 |
Why?
|
| Carcinoma | 8 | 2019 | 2327 | 0.260 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2018 | 487 | 0.260 |
Why?
|
| Ki-67 Antigen | 4 | 2006 | 627 | 0.260 |
Why?
|
| Leiomyoma | 4 | 2021 | 636 | 0.250 |
Why?
|
| Chromosome Deletion | 6 | 2010 | 1386 | 0.240 |
Why?
|
| Female | 123 | 2023 | 392148 | 0.240 |
Why?
|
| Venous Thromboembolism | 2 | 2019 | 1866 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 8 | 2021 | 2827 | 0.230 |
Why?
|
| Radioimmunotherapy | 2 | 1995 | 91 | 0.230 |
Why?
|
| Genes, BRCA2 | 7 | 2013 | 590 | 0.220 |
Why?
|
| Endometriosis | 3 | 2016 | 857 | 0.220 |
Why?
|
| Ovary | 7 | 2020 | 959 | 0.210 |
Why?
|
| Paget Disease, Extramammary | 2 | 2018 | 51 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2018 | 11736 | 0.210 |
Why?
|
| Middle Aged | 68 | 2021 | 220584 | 0.210 |
Why?
|
| Ovarian Cysts | 2 | 2016 | 108 | 0.200 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 1996 | 549 | 0.200 |
Why?
|
| Aged | 57 | 2021 | 169042 | 0.200 |
Why?
|
| Neoplasm Proteins | 6 | 2001 | 3607 | 0.200 |
Why?
|
| Pelvic Neoplasms | 3 | 2009 | 247 | 0.200 |
Why?
|
| Neoplasm Staging | 23 | 2020 | 11116 | 0.200 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2021 | 2020 | 0.190 |
Why?
|
| Cisplatin | 7 | 2016 | 1650 | 0.180 |
Why?
|
| Intraoperative Complications | 1 | 2007 | 1161 | 0.180 |
Why?
|
| Postoperative Complications | 6 | 2021 | 15612 | 0.180 |
Why?
|
| Adult | 58 | 2021 | 220969 | 0.170 |
Why?
|
| Aged, 80 and over | 27 | 2019 | 58894 | 0.170 |
Why?
|
| Humans | 131 | 2023 | 760617 | 0.170 |
Why?
|
| Germ-Line Mutation | 5 | 2013 | 1852 | 0.170 |
Why?
|
| Retrospective Studies | 32 | 2021 | 80566 | 0.170 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 5 | 1994 | 138 | 0.160 |
Why?
|
| Bronchial Fistula | 1 | 1999 | 83 | 0.160 |
Why?
|
| Chromosome Aberrations | 5 | 2010 | 1768 | 0.160 |
Why?
|
| Cicatrix | 1 | 2005 | 785 | 0.160 |
Why?
|
| Iodine Radioisotopes | 3 | 1992 | 1031 | 0.160 |
Why?
|
| Abdomen | 1 | 2005 | 1128 | 0.160 |
Why?
|
| Keratosis | 1 | 1999 | 79 | 0.160 |
Why?
|
| Neoplasm, Residual | 3 | 2019 | 1008 | 0.160 |
Why?
|
| Early Detection of Cancer | 3 | 2021 | 3196 | 0.150 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 218 | 0.150 |
Why?
|
| Tracheoesophageal Fistula | 1 | 1999 | 131 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2017 | 245 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 697 | 0.150 |
Why?
|
| Ascitic Fluid | 1 | 2018 | 189 | 0.150 |
Why?
|
| Cervix Uteri | 2 | 2021 | 570 | 0.150 |
Why?
|
| Skin Aging | 1 | 1999 | 140 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2013 | 4785 | 0.140 |
Why?
|
| Cyclin A1 | 1 | 2016 | 11 | 0.140 |
Why?
|
| Disease-Free Survival | 7 | 2019 | 6807 | 0.140 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2021 | 732 | 0.140 |
Why?
|
| Oocyte Retrieval | 1 | 2018 | 160 | 0.140 |
Why?
|
| Genes, ras | 4 | 2001 | 654 | 0.140 |
Why?
|
| Prognosis | 10 | 2019 | 29600 | 0.140 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 1996 | 40 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 8542 | 0.130 |
Why?
|
| Fallopian Tube Diseases | 1 | 2016 | 60 | 0.130 |
Why?
|
| Radioimmunodetection | 1 | 1995 | 45 | 0.130 |
Why?
|
| Ascites | 1 | 2018 | 338 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 5 | 1995 | 9172 | 0.130 |
Why?
|
| Adenocarcinoma, Mucinous | 4 | 2014 | 517 | 0.130 |
Why?
|
| Cell Proliferation | 5 | 2020 | 10432 | 0.130 |
Why?
|
| Immunohistochemistry | 10 | 2017 | 11069 | 0.130 |
Why?
|
| STAT6 Transcription Factor | 1 | 2016 | 194 | 0.130 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2016 | 168 | 0.120 |
Why?
|
| Fluorouracil | 6 | 2016 | 1642 | 0.120 |
Why?
|
| Immunotoxins | 1 | 1995 | 175 | 0.120 |
Why?
|
| Jews | 2 | 1999 | 356 | 0.120 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2016 | 67 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 17 | 5 | 1998 | 418 | 0.120 |
Why?
|
| RNA Precursors | 1 | 2016 | 200 | 0.120 |
Why?
|
| DNA, Neoplasm | 11 | 2003 | 1743 | 0.120 |
Why?
|
| Adnexa Uteri | 2 | 2019 | 40 | 0.120 |
Why?
|
| Carcinosarcoma | 1 | 2015 | 106 | 0.120 |
Why?
|
| CA-125 Antigen | 3 | 2013 | 276 | 0.120 |
Why?
|
| Chromosomes, Human | 2 | 2003 | 441 | 0.120 |
Why?
|
| Transcription Factors | 6 | 2000 | 12116 | 0.120 |
Why?
|
| Uterine Hemorrhage | 1 | 2016 | 240 | 0.120 |
Why?
|
| Paclitaxel | 4 | 2016 | 1730 | 0.110 |
Why?
|
| Frameshift Mutation | 1 | 1996 | 392 | 0.110 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 568 | 0.110 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2015 | 217 | 0.110 |
Why?
|
| Thymus Neoplasms | 1 | 1996 | 274 | 0.110 |
Why?
|
| Salvage Therapy | 2 | 2011 | 1263 | 0.110 |
Why?
|
| Microsatellite Repeats | 6 | 2000 | 783 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2018 | 2821 | 0.110 |
Why?
|
| Peritoneum | 2 | 2012 | 225 | 0.100 |
Why?
|
| Loss of Heterozygosity | 6 | 2000 | 662 | 0.100 |
Why?
|
| Skin Neoplasms | 4 | 2001 | 5812 | 0.100 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2017 | 380 | 0.100 |
Why?
|
| Organoids | 1 | 2018 | 744 | 0.100 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 5 | 2001 | 329 | 0.100 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2013 | 232 | 0.100 |
Why?
|
| Carboplatin | 5 | 2018 | 793 | 0.100 |
Why?
|
| Treatment Outcome | 16 | 2019 | 64568 | 0.100 |
Why?
|
| Lasers, Dye | 1 | 2011 | 28 | 0.090 |
Why?
|
| Bone Marrow Diseases | 1 | 1993 | 233 | 0.090 |
Why?
|
| Stomach Neoplasms | 5 | 2001 | 1453 | 0.090 |
Why?
|
| Cadherins | 1 | 2016 | 901 | 0.090 |
Why?
|
| Trophoblastic Neoplasms | 1 | 1991 | 88 | 0.090 |
Why?
|
| Chemoprevention | 1 | 2013 | 325 | 0.090 |
Why?
|
| Leiomyomatosis | 1 | 2010 | 69 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2020 | 3514 | 0.090 |
Why?
|
| DNA Repair | 2 | 2018 | 2043 | 0.090 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2018 | 1608 | 0.090 |
Why?
|
| Feasibility Studies | 7 | 2021 | 5239 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2008 | 1056 | 0.080 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1993 | 888 | 0.080 |
Why?
|
| Epithelial Cells | 3 | 2018 | 3672 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2016 | 1602 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2021 | 3461 | 0.080 |
Why?
|
| Lymph Node Excision | 4 | 2021 | 1269 | 0.080 |
Why?
|
| Cell Lineage | 1 | 2018 | 2554 | 0.080 |
Why?
|
| Immunologic Techniques | 1 | 1989 | 212 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2019 | 1529 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 8 | 2018 | 3593 | 0.080 |
Why?
|
| Nuclear Proteins | 3 | 2016 | 5789 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 1611 | 0.080 |
Why?
|
| Intraoperative Care | 1 | 2013 | 767 | 0.080 |
Why?
|
| Mutation | 15 | 2018 | 30016 | 0.080 |
Why?
|
| Lymphedema | 1 | 2015 | 523 | 0.080 |
Why?
|
| Granulosa Cell Tumor | 1 | 2009 | 77 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 1996 | 10175 | 0.080 |
Why?
|
| Sensitivity and Specificity | 5 | 2021 | 14648 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1996 | 1372 | 0.080 |
Why?
|
| Biopsy | 4 | 2016 | 6762 | 0.080 |
Why?
|
| Reoperation | 2 | 2020 | 4300 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 2015 | 1189 | 0.070 |
Why?
|
| Ultrasonography | 5 | 2005 | 5964 | 0.070 |
Why?
|
| Mass Screening | 3 | 2006 | 5424 | 0.070 |
Why?
|
| Receptors, Notch | 1 | 2012 | 743 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2016 | 1134 | 0.070 |
Why?
|
| Diagnosis, Differential | 6 | 2021 | 12966 | 0.070 |
Why?
|
| Lymphoma | 1 | 1996 | 1899 | 0.070 |
Why?
|
| Esophagectomy | 2 | 2008 | 467 | 0.070 |
Why?
|
| Obesity, Morbid | 1 | 2018 | 1276 | 0.070 |
Why?
|
| Pluripotent Stem Cells | 1 | 2014 | 796 | 0.070 |
Why?
|
| Gynecology | 1 | 2013 | 526 | 0.070 |
Why?
|
| Ovarian Diseases | 2 | 2008 | 136 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2014 | 1606 | 0.070 |
Why?
|
| Lymphatic Metastasis | 6 | 2015 | 2913 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2018 | 1937 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 2 | 2007 | 1051 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2021 | 3599 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2021 | 3481 | 0.070 |
Why?
|
| Survival Rate | 7 | 2020 | 12719 | 0.070 |
Why?
|
| DNA-Binding Proteins | 4 | 2016 | 9586 | 0.070 |
Why?
|
| RNA, Messenger | 6 | 2018 | 12758 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 2 | 2012 | 1350 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2018 | 2495 | 0.060 |
Why?
|
| Needs Assessment | 1 | 2012 | 1139 | 0.060 |
Why?
|
| Genital Neoplasms, Male | 1 | 2006 | 68 | 0.060 |
Why?
|
| Blood Vessels | 2 | 2010 | 1113 | 0.060 |
Why?
|
| Artifacts | 2 | 2010 | 1910 | 0.060 |
Why?
|
| Obesity | 2 | 2020 | 12933 | 0.060 |
Why?
|
| Sarcoma, Synovial | 1 | 2006 | 153 | 0.060 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 2568 | 0.060 |
Why?
|
| Risk Factors | 12 | 2023 | 74115 | 0.060 |
Why?
|
| Antineoplastic Agents | 4 | 2019 | 13635 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 5304 | 0.060 |
Why?
|
| Photochemotherapy | 1 | 2011 | 823 | 0.060 |
Why?
|
| Corpus Luteum | 1 | 2004 | 81 | 0.060 |
Why?
|
| MicroRNAs | 2 | 2018 | 3805 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 1996 | 322 | 0.060 |
Why?
|
| Case-Control Studies | 6 | 2015 | 22148 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2010 | 872 | 0.060 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2005 | 126 | 0.060 |
Why?
|
| Cell Movement | 2 | 2016 | 5200 | 0.060 |
Why?
|
| Patient Readmission | 2 | 2020 | 3269 | 0.060 |
Why?
|
| Base Sequence | 6 | 1998 | 12421 | 0.060 |
Why?
|
| Abdominal Neoplasms | 1 | 2005 | 287 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 2048 | 0.050 |
Why?
|
| Data Collection | 1 | 2013 | 3315 | 0.050 |
Why?
|
| Robotics | 3 | 2018 | 816 | 0.050 |
Why?
|
| Exons | 3 | 2008 | 2381 | 0.050 |
Why?
|
| Cystadenocarcinoma | 2 | 1993 | 54 | 0.050 |
Why?
|
| Colorectal Neoplasms | 2 | 2017 | 6925 | 0.050 |
Why?
|
| Esophagus | 2 | 2007 | 1031 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 4408 | 0.050 |
Why?
|
| Body Mass Index | 3 | 2016 | 12943 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 10 | 2001 | 6074 | 0.050 |
Why?
|
| Anilides | 1 | 2006 | 411 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 6126 | 0.050 |
Why?
|
| Cohort Studies | 5 | 2021 | 41457 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2005 | 629 | 0.050 |
Why?
|
| Point Mutation | 2 | 2000 | 1595 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 3634 | 0.050 |
Why?
|
| G1 Phase | 1 | 2003 | 403 | 0.050 |
Why?
|
| Antibodies | 1 | 1990 | 2414 | 0.050 |
Why?
|
| Molecular Sequence Data | 6 | 1998 | 17629 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2015 | 3442 | 0.050 |
Why?
|
| Radiography, Abdominal | 1 | 2005 | 534 | 0.050 |
Why?
|
| Brachytherapy | 2 | 2006 | 1223 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2012 | 2187 | 0.050 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 16967 | 0.050 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2001 | 52 | 0.050 |
Why?
|
| Hernia, Ventral | 1 | 2005 | 218 | 0.050 |
Why?
|
| Estrogen Receptor alpha | 1 | 2006 | 583 | 0.050 |
Why?
|
| Age Distribution | 1 | 2007 | 2871 | 0.050 |
Why?
|
| Survivors | 1 | 2012 | 2372 | 0.050 |
Why?
|
| Combined Modality Therapy | 5 | 2010 | 8516 | 0.050 |
Why?
|
| Alleles | 6 | 2000 | 6861 | 0.050 |
Why?
|
| Isoflavones | 1 | 2001 | 136 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2013 | 2317 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2007 | 1110 | 0.050 |
Why?
|
| Leukopenia | 1 | 2001 | 213 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2013 | 3900 | 0.040 |
Why?
|
| Endometrial Hyperplasia | 1 | 2021 | 97 | 0.040 |
Why?
|
| Cell Differentiation | 3 | 2014 | 11514 | 0.040 |
Why?
|
| Adenocarcinoma | 4 | 2006 | 6340 | 0.040 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2000 | 28 | 0.040 |
Why?
|
| Colposcopy | 1 | 2021 | 149 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 3351 | 0.040 |
Why?
|
| Vulva | 1 | 2000 | 84 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2008 | 1396 | 0.040 |
Why?
|
| Germ Cells | 1 | 2023 | 634 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2018 | 17878 | 0.040 |
Why?
|
| Doxorubicin | 3 | 2016 | 2224 | 0.040 |
Why?
|
| Gastroscopy | 1 | 2001 | 211 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6474 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 4570 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2000 | 367 | 0.040 |
Why?
|
| DNA Mutational Analysis | 5 | 2001 | 4110 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 3599 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2005 | 1070 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2001 | 279 | 0.040 |
Why?
|
| Omentum | 1 | 2019 | 167 | 0.040 |
Why?
|
| Online Systems | 1 | 2019 | 182 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 1999 | 184 | 0.040 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 9417 | 0.040 |
Why?
|
| Cell Division | 4 | 1999 | 4457 | 0.040 |
Why?
|
| Genetic Markers | 4 | 1998 | 2601 | 0.040 |
Why?
|
| Predictive Value of Tests | 6 | 2013 | 15251 | 0.040 |
Why?
|
| Streptococcus | 1 | 1998 | 197 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2006 | 1670 | 0.040 |
Why?
|
| Gene Regulatory Networks | 2 | 2017 | 1745 | 0.040 |
Why?
|
| Time Factors | 6 | 2020 | 39913 | 0.040 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 2 | 1994 | 68 | 0.040 |
Why?
|
| Camptothecin | 1 | 2001 | 591 | 0.040 |
Why?
|
| Karyotyping | 2 | 1996 | 1171 | 0.040 |
Why?
|
| Androgen Antagonists | 1 | 2006 | 1409 | 0.030 |
Why?
|
| Parity | 2 | 2009 | 924 | 0.030 |
Why?
|
| Organ Specificity | 2 | 2017 | 1964 | 0.030 |
Why?
|
| Osteonectin | 1 | 1996 | 33 | 0.030 |
Why?
|
| Drug Therapy | 1 | 1999 | 503 | 0.030 |
Why?
|
| Stomach | 1 | 2001 | 695 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2005 | 1396 | 0.030 |
Why?
|
| Cytogenetics | 1 | 1996 | 198 | 0.030 |
Why?
|
| Antibody Formation | 2 | 1992 | 1390 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2001 | 1022 | 0.030 |
Why?
|
| Carcinoma, Papillary | 2 | 2000 | 785 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 2016 | 397 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 794 | 0.030 |
Why?
|
| Clone Cells | 2 | 1998 | 1657 | 0.030 |
Why?
|
| Radiation Chimera | 1 | 1996 | 215 | 0.030 |
Why?
|
| Esophagoscopy | 2 | 2008 | 397 | 0.030 |
Why?
|
| Young Adult | 4 | 2016 | 59179 | 0.030 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 39063 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 9026 | 0.030 |
Why?
|
| Co-Repressor Proteins | 1 | 2016 | 189 | 0.030 |
Why?
|
| Transglutaminases | 1 | 2016 | 196 | 0.030 |
Why?
|
| Survival Analysis | 4 | 2007 | 10073 | 0.030 |
Why?
|
| Centromere | 1 | 1996 | 212 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1993 | 5672 | 0.030 |
Why?
|
| Mice | 8 | 2020 | 81368 | 0.030 |
Why?
|
| Etanidazole | 1 | 1994 | 22 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 550 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1088 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2021 | 3087 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 2 | 1992 | 412 | 0.030 |
Why?
|
| Diathermy | 1 | 1994 | 17 | 0.030 |
Why?
|
| DNA Damage | 3 | 2012 | 2446 | 0.030 |
Why?
|
| Epithelium | 4 | 2006 | 1603 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1995 | 310 | 0.030 |
Why?
|
| Follicular Phase | 1 | 1994 | 143 | 0.030 |
Why?
|
| Length of Stay | 2 | 2021 | 6418 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2018 | 878 | 0.030 |
Why?
|
| Triage | 1 | 2021 | 983 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1995 | 375 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2000 | 1755 | 0.030 |
Why?
|
| Vagina | 2 | 2004 | 841 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1996 | 783 | 0.030 |
Why?
|
| Immunotherapy | 1 | 1989 | 4642 | 0.030 |
Why?
|
| Gene Deletion | 3 | 1996 | 2661 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 3800 | 0.030 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1995 | 340 | 0.030 |
Why?
|
| Leukapheresis | 1 | 1993 | 134 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2001 | 1182 | 0.030 |
Why?
|
| Gonadotropins | 1 | 1994 | 241 | 0.030 |
Why?
|
| Galactose | 1 | 1994 | 294 | 0.030 |
Why?
|
| Mesna | 2 | 2006 | 62 | 0.030 |
Why?
|
| Male | 15 | 2013 | 360358 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2001 | 3777 | 0.030 |
Why?
|
| Oocytes | 1 | 2018 | 1166 | 0.030 |
Why?
|
| Observer Variation | 1 | 2019 | 2606 | 0.030 |
Why?
|
| Chromosomes | 1 | 1996 | 578 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 1999 | 2897 | 0.030 |
Why?
|
| Eating | 1 | 1999 | 1535 | 0.030 |
Why?
|
| Radiotherapy | 1 | 1999 | 1497 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1995 | 638 | 0.030 |
Why?
|
| Pyrazines | 1 | 2018 | 1202 | 0.030 |
Why?
|
| Ifosfamide | 2 | 2006 | 232 | 0.030 |
Why?
|
| Filgrastim | 2 | 2005 | 132 | 0.030 |
Why?
|
| Apoptosis | 2 | 2020 | 9476 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 13382 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2016 | 949 | 0.020 |
Why?
|
| Neoplasms | 3 | 1998 | 22131 | 0.020 |
Why?
|
| Animals | 10 | 2020 | 168201 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 1998 | 1079 | 0.020 |
Why?
|
| Prospective Studies | 5 | 2021 | 54360 | 0.020 |
Why?
|
| Dihematoporphyrin Ether | 1 | 2011 | 33 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 2467 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 2191 | 0.020 |
Why?
|
| Polymorphism, Genetic | 3 | 1998 | 4242 | 0.020 |
Why?
|
| DNA Replication | 1 | 2018 | 1414 | 0.020 |
Why?
|
| Cell Survival | 2 | 2016 | 5780 | 0.020 |
Why?
|
| Codon | 1 | 1993 | 600 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 4512 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2019 | 1037 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 8998 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 1994 | 2218 | 0.020 |
Why?
|
| Injections | 1 | 1994 | 832 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2016 | 1088 | 0.020 |
Why?
|
| Lidocaine | 1 | 1994 | 538 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 2010 | 135 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2016 | 1118 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 23416 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 1994 | 1496 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 407 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 1784 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 1996 | 1392 | 0.020 |
Why?
|
| Adenoma | 1 | 2001 | 2159 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 270 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 1993 | 539 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1999 | 2894 | 0.020 |
Why?
|
| Gravitation | 1 | 2009 | 82 | 0.020 |
Why?
|
| Adsorption | 1 | 1989 | 197 | 0.020 |
Why?
|
| Liver | 1 | 2005 | 7512 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2010 | 473 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2016 | 3088 | 0.020 |
Why?
|
| Incidence | 1 | 2007 | 21337 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 1992 | 4533 | 0.020 |
Why?
|
| Recombinant Proteins | 3 | 2005 | 6520 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 1991 | 457 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 2639 | 0.020 |
Why?
|
| RNA Interference | 1 | 2017 | 2830 | 0.020 |
Why?
|
| Taxoids | 1 | 2012 | 667 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 1662 | 0.020 |
Why?
|
| Risk Assessment | 3 | 2021 | 23972 | 0.020 |
Why?
|
| Cryopreservation | 1 | 1993 | 728 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2018 | 2008 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1996 | 1985 | 0.020 |
Why?
|
| New England | 1 | 1991 | 1051 | 0.020 |
Why?
|
| Radiation Dosage | 2 | 2008 | 1956 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2016 | 2446 | 0.020 |
Why?
|
| Cell Death | 1 | 2012 | 1677 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 2009 | 553 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 4571 | 0.020 |
Why?
|
| Photosensitizing Agents | 1 | 2011 | 623 | 0.020 |
Why?
|
| Gene Expression | 2 | 2016 | 7568 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 2872 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2021 | 3797 | 0.020 |
Why?
|
| DNA Methylation | 2 | 2017 | 4391 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 2001 | 1989 | 0.020 |
Why?
|
| Tosyl Compounds | 1 | 2006 | 115 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1989 | 1972 | 0.020 |
Why?
|
| Breast Neoplasms | 4 | 2003 | 20988 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2008 | 562 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 2008 | 603 | 0.020 |
Why?
|
| Blotting, Southern | 2 | 1998 | 777 | 0.020 |
Why?
|
| Massachusetts | 1 | 2018 | 8833 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1996 | 3688 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 2252 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 2635 | 0.020 |
Why?
|
| Remission Induction | 1 | 1991 | 2391 | 0.020 |
Why?
|
| Heterozygote | 3 | 1996 | 2780 | 0.010 |
Why?
|
| Dosage Compensation, Genetic | 2 | 1998 | 207 | 0.010 |
Why?
|
| Capillaries | 1 | 2008 | 756 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 2509 | 0.010 |
Why?
|
| Family Health | 1 | 2009 | 1253 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 2005 | 4845 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2012 | 2930 | 0.010 |
Why?
|
| Boston | 1 | 2017 | 9313 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2007 | 659 | 0.010 |
Why?
|
| DNA Primers | 2 | 2000 | 2817 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 2214 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1999 | 7995 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 20074 | 0.010 |
Why?
|
| Pilot Projects | 2 | 2008 | 8618 | 0.010 |
Why?
|
| Cysts | 1 | 2008 | 680 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 1993 | 2768 | 0.010 |
Why?
|
| Risk | 1 | 2014 | 9604 | 0.010 |
Why?
|
| Disease Progression | 3 | 2008 | 13495 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2003 | 880 | 0.010 |
Why?
|
| Phytoestrogens | 1 | 2001 | 59 | 0.010 |
Why?
|
| DNA Probes | 2 | 1993 | 541 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2003 | 368 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 2001 | 165 | 0.010 |
Why?
|
| Plant Preparations | 1 | 2001 | 94 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2006 | 1835 | 0.010 |
Why?
|
| Adolescent | 3 | 2016 | 88234 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2014 | 3548 | 0.010 |
Why?
|
| Electronics, Medical | 1 | 2001 | 72 | 0.010 |
Why?
|
| Logistic Models | 1 | 2015 | 13245 | 0.010 |
Why?
|
| Stomach Ulcer | 1 | 2001 | 122 | 0.010 |
Why?
|
| Phenotype | 1 | 2018 | 16571 | 0.010 |
Why?
|
| Nitriles | 1 | 2006 | 971 | 0.010 |
Why?
|
| Self Administration | 1 | 2001 | 387 | 0.010 |
Why?
|
| Genital Diseases, Female | 1 | 2001 | 192 | 0.010 |
Why?
|
| Curettage | 1 | 2000 | 74 | 0.010 |
Why?
|
| Plants | 1 | 2001 | 327 | 0.010 |
Why?
|
| Prevalence | 1 | 2017 | 15689 | 0.010 |
Why?
|
| Computer Systems | 1 | 2001 | 469 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2001 | 573 | 0.010 |
Why?
|
| Chromosome Mapping | 2 | 2000 | 4611 | 0.010 |
Why?
|
| WT1 Proteins | 1 | 2000 | 184 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2001 | 1301 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2001 | 749 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 1703 | 0.010 |
Why?
|
| Pregnancy | 2 | 2009 | 29868 | 0.010 |
Why?
|
| Histones | 1 | 2008 | 2577 | 0.010 |
Why?
|
| Cell Transformation, Viral | 2 | 1995 | 526 | 0.010 |
Why?
|
| Trinucleotide Repeats | 1 | 1998 | 257 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2008 | 2881 | 0.010 |
Why?
|
| Chondroitin | 1 | 1977 | 64 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2000 | 1150 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1996 | 372 | 0.010 |
Why?
|
| Chondroitin Sulfates | 1 | 1977 | 174 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2001 | 1813 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1997 | 531 | 0.010 |
Why?
|
| Safety | 1 | 2001 | 1149 | 0.010 |
Why?
|
| Sodium | 1 | 2001 | 1588 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 11874 | 0.010 |
Why?
|
| Postmenopause | 1 | 2004 | 2511 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1996 | 313 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 1242 | 0.010 |
Why?
|
| Intermediate Filaments | 1 | 1995 | 171 | 0.010 |
Why?
|
| X Chromosome | 1 | 1998 | 816 | 0.010 |
Why?
|
| Lactose | 1 | 1994 | 95 | 0.010 |
Why?
|
| Brain | 1 | 2021 | 27101 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 26049 | 0.010 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 1998 | 1033 | 0.010 |
Why?
|
| Methotrexate | 1 | 2001 | 1716 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1998 | 2178 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 36402 | 0.010 |
Why?
|
| Proteoglycans | 1 | 1977 | 803 | 0.010 |
Why?
|
| ROC Curve | 1 | 2001 | 3575 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1998 | 1471 | 0.010 |
Why?
|
| Hyaluronic Acid | 1 | 1977 | 483 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 2801 | 0.010 |
Why?
|
| Estrogens | 1 | 2000 | 1521 | 0.010 |
Why?
|
| Morphogenesis | 1 | 1977 | 741 | 0.010 |
Why?
|
| Menstruation | 1 | 1994 | 306 | 0.010 |
Why?
|
| Neutropenia | 1 | 1998 | 885 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 18381 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2003 | 8311 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1994 | 726 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2000 | 1745 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 3447 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 1994 | 820 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1996 | 1490 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1991 | 260 | 0.010 |
Why?
|
| Anesthesia, Local | 1 | 1994 | 277 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 1788 | 0.010 |
Why?
|
| Dairy Products | 1 | 1994 | 490 | 0.010 |
Why?
|
| Splenectomy | 1 | 1992 | 389 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 4172 | 0.010 |
Why?
|
| Premenopause | 1 | 1994 | 1038 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1995 | 1202 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2001 | 4910 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1996 | 3605 | 0.010 |
Why?
|
| Age of Onset | 1 | 1996 | 3302 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1989 | 157 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1993 | 592 | 0.000 |
Why?
|
| Dietary Supplements | 1 | 2001 | 3411 | 0.000 |
Why?
|
| Transfection | 1 | 1996 | 5766 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 7583 | 0.000 |
Why?
|
| United States | 1 | 2015 | 72272 | 0.000 |
Why?
|
| Transforming Growth Factor beta | 1 | 1995 | 1963 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 2001 | 12043 | 0.000 |
Why?
|
| Estradiol | 1 | 1994 | 1937 | 0.000 |
Why?
|
| Platelet Count | 1 | 1989 | 780 | 0.000 |
Why?
|
| Colonic Neoplasms | 1 | 1998 | 2533 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1994 | 2410 | 0.000 |
Why?
|
| Feeding Behavior | 1 | 1994 | 3182 | 0.000 |
Why?
|
| DNA | 1 | 1994 | 7196 | 0.000 |
Why?
|
| Genotype | 1 | 1994 | 12978 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1995 | 18937 | 0.000 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 1977 | 136 | 0.000 |
Why?
|
| Chick Embryo | 1 | 1977 | 982 | 0.000 |
Why?
|
| Cartilage | 1 | 1977 | 806 | 0.000 |
Why?
|
| Extremities | 1 | 1977 | 867 | 0.000 |
Why?
|
| Cornea | 1 | 1977 | 1332 | 0.000 |
Why?
|
| Collagen | 1 | 1977 | 2634 | 0.000 |
Why?
|
| Lipid Metabolism | 1 | 1977 | 1896 | 0.000 |
Why?
|